Richmond Pharmacology were pleased to provide our sponsor, Codiak BioSciences, with positive results of its exosome therapeutic exoIL-12.
Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.
View our latest peer-reviewed publications from a selection of our clinical trials.
Learn more about Richmond Pharmacology by viewing some of our videos.